Studienregister

Studienregister der Deutschen Gesellschaft für Urologie e.V.

MATuRITY

AcronymISRCTNEudraCTClinicaltrials.govDRKS
DIREG_R_04571

Management of Advanced prostate cancer in senior adults: a prospective international registry

Status: Active

Purpose / Objectives

Primary Outcome

To assess the impact of health status on the management of metastatic Castration – Refractory Prostate Cancer (mCRPC) in senior adults (≥70 years)

Secondary Outcomes

To evaluate the tolerability of treatment modalities in current practice in senior adults (≥70 years).

To evaluate PSA response, tumor response, progression-free survival and overall survival with different treatment modalities

Diagnosis

Patient attributes

Stage

Castration-refractory

Age

70-100

Inclusion criteria

- Men aged 70 years or older
- Prostate adenocarcinoma
- Metastatic CRPC with evidence of disease progression (PSA progression and/or occurrence of new metastases on chest X-ray, CT scan, MRI or bone scan)
- Testosterone at castrate level (<50 ng/dL)
- Patient’s consent obtained, with written Informed Consent Form signed and dated

Exclusion criteria

- Any prior chemotherapy for prostate cancer
- Any prior treatment for metastatic CRPC
- Treatment with non marketed agents
- Current participation in a clinical trial for prostate cancer

Trial design

  • Multicenter
  • Prospective

Intervention

Non-interventional on the therapeutic strategy

Documents (password protected)

Responsibilities in overall trial

Sanofi-Aventis

  • Tel. 0033 160497777
  • Fax 033 160497515

nach oben